Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
After stem printer is demerged whats next in the pipeline and what time scales do you think we're talking about? Thanks
There is this, pieces seem to fit.
https://news.bloomberglaw.com/pharma-and-life-sciences/gilead-announces-phase-1a-clinical-study-for-inhaled-remdesivir
Off the back of TILS RNS
https://www.tizianalifesciences.com/news-item?s=2020-06-29-agreement-with-stc-biologics-for-gmp-manufacturing-of-an-anti-interleukin-6-receptor-monoclonal-antibody-for-clinical-studies-in-patients-with-covid-19
It does, although Remdesivir is not a monoclonal antibody so I am not sure this would need our patented technology
Not a mAB but,
“ The proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment of COVID-19”
Dr Kunwar believes his patent does cover inhalation of Remdesivir.
Way too much to read tonight but full patent can be viewed here:
http://patft.uspto.gov/netahtml/PTO/srchnum.htm
Patent number : 10688186
Thank You Stims and TradePhoenix - all good information and if the patent dies indeed cover Remdesivir this could be very material
We should be kicking on in these positive markets but know why not.
Mind, last 4 months good overall if you were in and stayed.
https://www.google.com/amp/s/www.cnbc.com/amp/2020/07/08/stock-market-futures-open-to-close-news.html
From Ad fn bb
didn't mention this on here, but... we needed to burn 18m volume to kill the last warrants batch... Yesterday we hit 20m volume, warrants are done. It's Thursday tomorrow.. We are expecting phase 2 trails news... not saying we will get news tomorrow, but AGM is close to Stem 1/1 cutoff, also big news is incoming...
Stims - I can see mention of enteric coated oral capsule and combination with 5-asa.
Not sure I can see inhaled or anything other than specific antibody. It is a TILS patent - maybe a different patent?
Rorke - somewhere in that Patent doc it does say nasal / aerosol administration but wouldn't consider myself qualified to comment much further.
In the recent Proactive interview Sanofi and Roche are mentioned by name as being covered by the patent when delivered by inhalation. Maybe this is what the NDA's are about?
Hi I'm new to the forum, tho I have been reading it for a couple of months now since I got interested in share dealing and I am a tiny investor compared to people here (£7k here out of a £25k thinly spread 17 company portfolio) (tho it is a lot to a shift worker like me).
Intro out of the way :)
I was reading the patent last night with interest and maybe this is the part you are looking for :
DETAILED DESCRIPTION
The present invention provides formulations and dosing for monoclonal antibodies, e.g., fully human monoclonal antibodies, specific against CD3 epsilon chain (CD3.epsilon.). Specifically, the invention provides oral, nasal and subcutaneous formulations of anti-CD3.epsilon. antibodies useful of target tissue specific immunomodulation. Unlike, systemic (e.g., intravenous) administration of anti-CD3 antibodies, the formulation of the present invention minimizes off target immunosuppression. An additional superior feature of the formulation of the invention, is the ability to dose at lower concentration of anti-CD3 antibodies than previously possible due to the target nature of the administration. The formulations are useful in treating or alleviating a symptom of autoimmune diseases, inflammatory disorders neurodegenerative disorders and cancer.
I am a little confused with all the different dates on the patent tho. Never read one till yesterday. :)
Cheers and welcome GTFC
Yep searched for aerosol - for some reason my name popped up